Evidence map›Paper›PMID 27112265›Full record

ArticleOrphanet journal of rare diseases2016

Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders.

Veronique Latger-Cannard, Christophe Philippe, Alexandre Bouquet, Veronique Baccini, Marie-Christine Alessi, Annick Ankri, Anne Bauters, Sophie Bayart, Pascale Cornillet-Lefebvre, Sylvie Daliphard and 10 more

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 102 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. GermlineEJHaem · 2023
    Article
  13. Review
  14. Genetic Predisposition to Hematologic Malignancies in Childhood and Adolescence.Mediterranean journal of hematology and infectious diseases · 2023
    Review
  15. Review
  16. Pathogenic Mechanisms in Acute Myeloid Leukemia.Current treatment options in oncology · 2022
    Review
  17. Beyond PathogenicCancers · 2022
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 2 countries.

Veronique Latger-CannardService d'Hématologie Biologique, Centre Hospitalier Universitaire de Nancy, Nancy, France.
Christophe PhilippeLaboratoire de Génétique, Centre Hospitalier Universitaire de Nancy, Nancy, France.
Alexandre BouquetService d'Hématologie Biologique, Centre de Biologie Pathologie, Centre Hospitalier Régional Universitaire de Lille, Lille, France.
Veronique BacciniLaboratoire d'Hématologie, Hôpital La Timone, Marseille, France.
Marie-Christine AlessiLaboratoire d'Hématologie, Hôpital La Timone, Marseille, France.
Annick AnkriAssistance Publique-Hôpitaux de Paris, Laboratoire d'Hématologie, La Pitié Salpetrière, Paris, France.
Anne BautersCentre de Compétence Nord-Est des Pathologies Plaquettaires (CCPP), Nancy, France.
Sophie BayartCentre Régional de Traitement des Hémophiles, Centre Hospitalier Universitaire de Rennes, Rennes, France.
Pascale Cornillet-LefebvreLaboratoire d'Hématologie, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Sylvie DaliphardLaboratoire d'Hématologie, Centre Hospitalier Universitaire Robert Debré, Reims, France.
Marie-Joelle MozziconacciDépartement de Biopathologie, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille, France.
Aline RennevilleService d'Hématologie Biologique, Centre de Biologie Pathologie, Centre Hospitalier Régional Universitaire de Lille, Lille, France.
Paola BalleriniAssistance Publique-Hôpitaux de Paris, Département d'Hématologie, Hôpital Armand Trousseau, Paris, France.
Guy LevergerAssistance Publique-Hôpitaux de Paris, Département d'Hématologie, Hôpital Armand Trousseau, Paris, France.
Hagay SobolDépartement de Biopathologie, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille, France.
Philippe JonveauxLaboratoire de Génétique, Centre Hospitalier Universitaire de Nancy, Nancy, France.
Claude PreudhommeService d'Hématologie Biologique, Centre de Biologie Pathologie, Centre Hospitalier Régional Universitaire de Lille, Lille, France.
Paquita NurdenLaboratoire d'Hématologie, Hôpital La Timone, Marseille, France.
Thomas LecompteService d'Hématologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
Remi FavierAssistance Publique-Hôpitaux de Paris, Département d'Hématologie, Hôpital Armand Trousseau, Paris, France. remi.favier@aphp.fr.
Centre Hospitalier Universitaire de Lille · FRHôpital de la Timone · FRCentre Hospitalier Régional et Universitaire de Nancy · FRCentre de Recherche en Cancérologie de Marseille · FRCentre Hospitalier Universitaire de Reims · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire de Rennes · FRHôpital Armand-Trousseau · FRHôpital Beau-Séjour · CHSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLess than 50 patients with FPD/AML (OMIM 601309) have been reported as of today and there may an underestimation. The purpose of this study was to describe the natural history, the haematological features and the genotype-phenotype correlations of this entity in order to, first, screen it better and earlier, before leukaemia occurrence and secondly to optimize appropriate monitoring and treatment, in particular when familial stem cell transplantation is considered.

methodsWe have investigated 41 carriers of RUNX1 alteration belonging to nine unrelated French families with FPD/AML and two syndromic patients, registered in the French network on rare platelet disorders from 2005 to 2015.

resultsFive missense, one non-sense, three frameshift mutations and two large deletions involving several genes including RUNX1 were evidenced. The history of familial leukaemia was suggestive of FPD/AML in seven pedigrees, whereas an autosomal dominant pattern of lifelong thrombocytopenia was the clinical presentation of two. Additional syndromic features characterized two large sporadic deletions. Bleeding tendency was mild and thrombocytopenia moderate (>50 x10(9)/L), with normal platelet volume. A functional platelet defect consistent with a δ-granule release defect was found in ten patients regardless of the type of RUNX1 alteration. The incidence of haematological malignancies was higher when the mutated RUNX1 allele was likely to cause a dominant negative effect (19/34) in comparison with loss of function alleles (3/9). A normal platelet count does not rule out the diagnosis of FPD/AML, since the platelet count was found normal for three mutated subjects, a feature that has a direct impact in the search for a related donor in case of allogeneic haematopoietic stem cell transplantation.

conclusionsPlatelet dysfunction suggestive of defective δ-granule release could be of values for the diagnosis of FPD/AML particularly when the clinical presentation is an autosomal dominant thrombocytopenia with normal platelet size in the absence of familial malignancies. The genotype-phenotype correlations might be helpful in genetic counselling and appropriate optimal therapeutic management.

Indexed as

AdolescentAdultBlood Coagulation Disorders, InheritedBlood Platelet DisordersChildChild, PreschoolComparative Genomic HybridizationCore Binding Factor Alpha 2 SubunitFemaleGenetic Association StudiesHumansInfantLeukemia, Myeloid, AcuteMaleMiddle AgedMutationCore Binding Factor Alpha 2 SubunitRUNX1 protein, humanFamilial platelet disorder with predisposition to acute myeloid leukaemiaLeukaemiaRUNX1Thrombocytopeniaδ-granule release defect

Identifiers

PMID27112265
PMCPMC4845427
OpenAlexW2343009125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.